Outcomes of kidney transplantation in patients with hepatitis B virus infection: A systematic review and meta-analysis

Table 1 Main characteristics of the studies assessing outcomes of kidney transplantation in patients with hepatitis B virus

Study	Lee et al[55]	Breitenfeldt et al[56]	Chan et al[21]	Morales et al[57]	Ridruejo et al[52]	Aroldi et al[53]	Yap et al[18]	Reddy et al[36]	Grenha et al[31]	Lee et al[54]
Country	Taiwan	Germany	Hong Kong	Spain	Argentina	Italy	Hong Kong	USA	Portugal	Korea
Study design	Cohort study	Cohort study	Cohort study	Cohort study	Cohort study	Cohort study	Cohort study	Cohort	Cohort study	Cohort study
Year	2001	2002	2002	2004	2004	2005	2010	2011	2015	2016
Total number	477	927	509	3365	231	541	126	75681	2284	3482
Age (yr)	38.6 ± 11.5	41.7	N/A	45.6 ± 13.0	38	31.7	49.2	N/A	44.3	40.6 ± 12.9
Male	280 (58.7%)	595 (64.2%)	N/A	2119 (63.0%)	136 (58.9%)	322 (59.5%)	90 (71.4%)	45249 (59.8%)	1524 (66.7%)	2084 (59.9%)
Living donor	N/A	19 (2.0%)	N/A	N/A	N/A	62 (11.5%)	41 (32.5%)	32096 (42.4%)	80 (3.5%)	2571 (73.8%)
HBsAg	62 (13.0%)	37 (4.0%)	67 (13.2%)	76 (2.2%)	17 (7.3%)	77 (14.2%)	63 (50%)	1346 (1.8%)	76 (3.3%)	160 (4.6%)
HBeAg in HbsAg (+) patients	N/A	11/37 (29.7%)	29/67 (43.3%)	N/A	N/A	34/77 (44.2%)	16/63 (25.4%)	N/A	N/A	N/A
HBV treatment	N/A	N/A	Lamivudine 26/67 (39%)	N/A	N/A	N/A	Lamivudine 38/63 (60%)	N/A	N/A	Not specified 129/160 (81%)
Anti-HCV	151 (31.7%)	130 (14.0%)	0 (0%)	513 (15.2%)	106 (45.9%)	244 (45.1%)	0 (0%)	0 (0%)	113 (4.9%)	55/3482 (1.6%)
Immunosuppression	Cyclosporine, steroid, azathioprine, MMF	N/A	Cyclosporine, steroid, azathioprine	Cyclosporine, steroid, azathioprine, MMF, FK506	Cyclosporine, steroid, azathioprine	Cyclosporine, steroid, azathioprine	Cyclosporine/tacrolimus, steroid, MMF	Cyclosporine/tacrolimus, steroid, azathioprine, MMF, mTOR	N/A	Cyclosporine/tacrolimus, steroid, azathioprine/MMF
Follow-up after KTx	6.0 ± 7.0 yr	9.2 ± 4.4 yr	82 ± 58 mo	N/A	39.9 (1-10.4.2) mo	11 yr	140.1 mo	1098 d	10 yr	89.1 ± 54.1 mo
Mortality	Overall	Overall	No HCV	Overall	Overall	Overall	No HCV	Overall	Overall	2.37 (1.16-4.87)
	2.72 (1.48-4.99)	4.08 (2.10-7.93)	8.07 (3.65-17.86)	2.06 (1.24-3.40)	2.20 (0.57-8.34)	2.36 (1.50-3.70)	11.70 (1.45-94.40)	1.07 (0.88-1.31)	1.33 (0.78-2.29)
	No HCV	No HCV		No HCV		No HCV		Living donor	No HCV
	4.61 (2.41-8.84)	3.60 (1.72-7.54)		2.97 (1.66-5.33)		4.40 (2.06-9.41)		0.98 (0.59-1.63)	1.02 (0.54-1.94)
								Deceased donor
								1.09 (0.88-1.36)
Graft failure	Overall	Overall	No HCV	Overall	5.45 (1.95-15.23)	Overall	N/A	Overall	Overall	1.38 (0.55-3.50)
	1.84 (1.08-3.15)	2.07 (1.06-4.05)	1.61 (0.86-3.03)	0.62 (0.37-1.02)		1.55 (1.12-2.14)		1.02 (0.81-1.28)	1.57 (0.99-2.49)
	No HCV	No HCV		No HCV		No HCV		Living donor	No HCV
	3.56 (1.89-6.71)	1.48 (0.71-3.08)		0.59 (0.32-1.09)		0.65 (0.27-1.54)		0.90 (0.62-1.30)	1.63 (0.98-2.71)
								Deceased donor
								1.10 (0.82-1.47)
Confounder adjustment	None	None	None	None	None	Age, Hepatitis C status	none	Recipient age, gender, BMI, race, comorbid, dialysis duration, donor HBcAb, expanded criteria donor, HLA DR mismatch, cold ischemia time, induction therapy, immunosuppressants	none	Age, sex, DM, BMI, primary renal disease, donor type, hypertension, ischemic heart disease, immunosuppressive agents
New Castle-Ottawa score	S 4	S 4	S 4	S 4	S 4	S 4	S 4	S 4	S 4	S 4
	C 0	C 0	C 0	C 0	C 0	C 1	C 0	C 2	C 0	C 2
	O 3	O 3	O 3	O 3	O 3	O 3	O 3	O 3	O 3	O 3

FK506: Tacrolimus; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; HCV: Hepatitis C virus; KTx: Kidney transplantation; MMF: Mycophenolate mofetil; S, C, O: Selection, comparability, and outcome.